Overview
Arik Drucker practices practicing medicine in Halifax, Canada.
His clinical expertise encompasses HER-2 Positive Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Breast Cancer.
He is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Arik Drucker
Is Arik Drucker a top-rated expert for HER-2 Positive Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Arik Drucker is classified as an Experienced expert for HER-2 Positive Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Arik Drucker participate in research or clinical trials?
Yes. Arik Drucker has published 9 articles and abstracts on conditions like HER-2 Positive Breast Cancer. You can view a list of Arik Drucker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Breast CancerMr. Drucker isExperienced. Learn about Breast Cancer.
- HER-2 Positive Breast CancerMr. Drucker isExperienced. Learn about HER-2 Positive Breast Cancer.
- PIK3CA-Related Overgrowth SpectrumMr. Drucker isExperienced. Learn about PIK3CA-Related Overgrowth Spectrum.